The Cigna Group logo

The Cigna Group(CI)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
Consider higher Upturn Star rating
BUY for 22 days
PROFIT SINCE LAST BUY
-0.61% ▼
LAST CLOSE
$297
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for CI

11/13/2026: CI (1-star) has a low Upturn Star Rating. Not recommended to BUY.

The Cigna Group is a major healthcare services company operating through its Evernorth pharmacy solutions and Cigna Healthcare insurance divisions. The company's primary strength lies in its integrated business model and scale in pharmacy benefit management, which drives steady cash flow generation. Its core growth strategy centers on expanding specialty pharmacy services and value-based care partnerships. However, key risks include heavy regulatory scrutiny regarding drug pricing and ongoing exposure to medical cost inflation. Suited for value and dividend-focused investors, market participants should closely monitor legislative developments affecting PBM transparency and medical loss ratios.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitCigna offers steady mid-single-digit top-line growth rather than high-octane hyper-growth.
Momentum investorStrong fit while signal remains positiveMomentum fit is conditional on a positive technical and fundamental upturn signal in the healthcare sector.
Value investorStrong fitThe stock frequently trades at reasonable price-to-earnings multiples relative to its strong cash flow generation.
Dividend investorStrong fitCigna provides a reliable and growing dividend supported by robust free cash flow.
Low-risk investorMixed fitWhile defensive, the stock remains subject to headline risks regarding healthcare policy and regulatory scrutiny.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMediumThe stock experiences moderate price swings driven by quarterly medical cost trends and regulatory headlines.
Valuation riskLowShares typically trade at reasonable valuations, limiting severe multiple contraction risk.
Competition risk (PBM and managed care competition)Medium / highIntense rivalry with giants like UnitedHealth and CVS Health shapes market pricing power.
Business qualityStrongThe company possesses a durable franchise with entrenched positions in corporate health and pharmacy services.
Dividend incomeMediumPayouts are secure and growing, though yields are supplemented heavily by share repurchases.
Execution riskMediumManagement must continuously execute complex pharmacy management and medical cost containment strategies.

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 78.26B USD
Price to earnings Ratio 13.1
1Y Target Price 344.96
Price to earnings Ratio 13.1
1Y Target Price 344.96
Volume (30-day avg) 1.6M shares
Beta 0.25
52 Weeks Range 253.96 - 318.05
Updated Date 11/15/2026
52 Weeks Range 253.96 - 318.05
Updated Date 11/15/2026
Dividends yield (FY) 2.09%
Basic EPS (TTM) 22.68

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Healthcare Plans

BUY participation
60.0%
Active BUY / eligible
3 / 5
30-Day BUY Count Change
+1

Eligible universe: 5 stocks.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steady Uptrend
PRICE PATH

Steady Uptrend

The stock demonstrates consistent and steady upward price momentum.

Smooth
PRICE STABILITY

Smooth

The stock has moved along a generally orderly path with only modest fluctuations.

Analysis of Past Performance

Type Stock
Historic Profit -41.74%
Avg. Invested days 30
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
CI receives a 3-star rating, supported by solid company fundamentals, solid quantitative characteristics, and solid analyst coverage. The rating is constrained by soft unit economics, and weak price momentum.

Company Fundamentals

★★★★★
CI has solid overall fundamentals (4 stars), with moderate financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+73.5%) and solid revenue growth (+11.3%) are partially offset by soft cash generation (FCF margin 3.1%), soft profitability (net margin 2.2%), modest insider ownership of 1.62%.

Financial Health Rating

★★★★★
CI's financial health is supported by strong cash strength, including free-cash-flow generation of $8.4B (3.1% of revenue). Profitability is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is CI's strongest growth driver at +73.5% FY2025 versus FY2024 (strong, 5 stars). By comparison, revenue growth (+11.3%, solid) is also solid, while free-cash-flow growth (-6.3%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 91.1% and approximately 99.5% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 1.62% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 8.89%
Vanguard Capital Management, LLC 6.56%
State Street Corp 4.81%
Dodge & Cox 4.62%
Massachusetts Financial Services Company 3.96%

Unit Economics (Per $1K Revenue)

★★★★★
CI generates approximately $95 of gross profit, $33 of operating income, and $31 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 2-star rating, with moderate cash conversion and moderate capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 17.71%

Quantitative Style Profile

★★★★★
CI has a large-cap, liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilityLarge / Mega Cap StabilityHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Evernorth Health ServicesPharmacy benefit management, specialty pharmacy, home delivery, and health services solutions.This is the company's primary revenue engine, generating steady cash flows from managing prescription drug programs.
Cigna HealthcareMedical, dental, and supplemental health insurance products for employers and individuals.Generates revenue through premium collections and fee-based administrative services for employer health plans.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-11-05
When Before Market
Estimate 7.46
Actual 7.98

Profitability

Profit Margin 2.09%
Operating Margin (TTM) 3.79%

Management Effectiveness

Return on Assets (TTM) 4.29%
Return on Equity (TTM) 15.65%

Valuation

Trailing PE 13.1
Forward PE 8.86
Enterprise Value 102.17B
Price to Sales(TTM) 0.27
Enterprise Value 102.17B
Price to Sales(TTM) 0.27
Enterprise Value to Revenue 0.36
Enterprise Value to EBITDA 8.02
Shares Outstanding 263.50M
Shares Floating 262.20M
Shares Outstanding 263.50M
Shares Floating 262.20M
Percent Insiders 1.62
Percent Institutions 91.05

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.